{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-119844","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.953880+00:00","generated_at":"2026-05-15T09:21:14.853053+00:00","sec_items":["1.02","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Sutro Biopharma reports FY2025 revenue $102.5M; cash runway extended into Q2 2028","bullets":["Cash $141.4M at Dec 31, 2025; $110M underwritten offering extends runway into Q2 2028.","Revenue $102.5M (FY2025) vs $62.0M in 2024; R&D+G&A expenses reduced to $207.4M from $300.5M.","Terminated ATM Sales Agreement with Jefferies effective March 23, 2026.","STRO-004 Phase 1 dosed three cohorts; initial data mid-2026. STRO-227 IND submission on track for 2026.","Astellas TROP2 iADC program entered clinic; $10M milestone expected Q2 2026. Second program triggers $7.5M milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-119844","json":"https://secwatch.observer/filing/0001193125-26-119844.json","markdown":"https://secwatch.observer/filing/0001193125-26-119844.md","text":"https://secwatch.observer/filing/0001193125-26-119844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/0001193125-26-119844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/stro-20260323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:21:14.853053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4797d55ebdb8cde9b52213afd25674b6ae568e73","claim":"SUTRO BIOPHARMA, INC. reported financial results for the full year 2025.","evidence_excerpt":"On March 23, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/0001193125-26-119844-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"89de926e34215f7aa3f736f89ea928072f9d407d","claim":"SUTRO BIOPHARMA, INC. terminated Sales Agreement with Jefferies LLC (effective 2026-03-23).","evidence_excerpt":"On March 23, 2026, the Company and Agent mutually agreed to terminate the Sales Agreement effective immediately as of March 23, 2026.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/0001193125-26-119844-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Effective","value":"2026-03-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}